Cornered by critics, top FDA officials stand by Aduhelm OK amid calls to reform accelerated approval process
Biogen’s Aduhelm has triggered a fresh round of debate between the FDA, public health experts and doctors on the pages of a prestigious medical journal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
